
The Seasonal Malaria Chemoprevention program protects children from malaria by distributing preventative medication at times of high transmission.
Malaria kills around 600,000 people each year, the majority of whom are children under 5. Malaria Consortium reports that malaria, a preventable and treatable disease, threatens 3.2 billion people globally.
Malaria Consortium’s mission is “to improve lives in Africa and Asia through sustainable, evidence-based programmes that combat targeted diseases and promote universal health coverage.”
Malaria Consortium fights malaria and other diseases through a variety of strategies and programmes. Its seasonal malaria chemoprevention (SMC) programme distributes preventative antimalarial drugs to young children, who are most vulnerable to the disease, during times of peak malaria transmission.
Through its SMC programme, Malaria Consortium:
Malaria Consortium’s SMC programme is named a Top Charity for preventing malaria by the impact-focused charity evaluator GiveWell, which we looked into as part of our 2025 evaluator investigations. We concluded that GiveWell’s recommendations are well-suited to helping donors maximise the impact of their “dollar” in the global health and wellbeing space. You can read our report on GiveWell here, and GiveWell’s extensive evaluation of Malaria Consortium’s SMC programme, which highlights its cost-effectiveness, here.
Malaria Consortium’s SMC programme has been a GiveWell Top Charity since 2016. GiveWell estimates that the cost of protecting one child from malaria through this program is about $7 — $1.66 for one of (typically) four monthly treatments and that approximately $5000 is enough to save a life.